Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the closing of its previously announced upsized underwritten public offering of 9,961,538 American depositary shares (ADSs), each representing three ordinary shares, which includes the full exercise of the underwriters' option to purchase up to 1,500,000 additional ADSs at a price to the public of $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at a price to the public of $64.9999 per pre-funded warrant. All of the securities in the offering were sold by Structure Therapeutics.

GlobeNewsWire • Dec 11, 2025

In The 'Uber Bull' Biotech Market, Is Structure The Next Metsera?

In a post-Metsera world, Structure Therapeutics could be the next big takeover candidate, analysts said Tuesday.

Investors Business Daily • Dec 9, 2025

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the pricing of its upsized underwritten public offering of 8,461,538 American depositary shares (ADSs), each representing three ordinary shares, at a price to the public of $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at a price to the public of $64.9999 per pre-funded warrant. All of the securities in the offering are being sold by Structure Therapeutics.

GlobeNewsWire • Dec 10, 2025

GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron

Structure Therapeutics jumps after phase II data show aleniglipron delivering strong, durable weight-loss results across multiple studies.

Zacks Investment Research • Dec 9, 2025

Structure Therapeutics: Phase 2b Puts Aleniglipron In The Oral GLP-1 Top Tier (Rating Upgrade)

Structure Therapeutics (GPCR) delivered robust Phase 2b results for aleniglipron, surpassing key efficacy and tolerability thresholds for oral GLP-1 therapies. GPCR now appears competitive with top oral obesity drugs, with dose optimization and front-end titration as critical levers for further differentiation. Recent $500M stock offering, combined with $800M cash, positions GPCR as 'Phase 3 ready' but valuation reflects high expectations.

Seeking Alpha • Dec 9, 2025

Structure's experimental pill shows 11% weight loss in study, shares up

Structure Therapeutics said on Monday that its obesity pill showed a 11.3% reduction in weight in a mid-stage study.

Reuters • Dec 8, 2025

Structure Therapeutics Soars; CEO Says It Could Have 'Best-In-Class' Weight-Loss Drug

Structure Therapeutics said Monday patients who took its obesity treatment lost up to 15.3% more body weight than placebo recipients.

Investors Business Daily • Dec 8, 2025

Why Structure Therapeutics Stock Doubled and Then Some on Monday

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron.

The Motley Fool • Dec 9, 2025

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Structure Therapeutics stock (NASDAQ: GPCR) rocketed above 103% Monday, trading near $70, after the clinical-stage biotech released promising mid-stage results for its oral obesity drug, aleniglipron. The surge, which nearly doubles the company's market cap in a single session, signals that Wall Street sees a viable new contender in the lucrative weight-loss market.

Invezz • Dec 8, 2025

Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript

Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript

Seeking Alpha • Dec 9, 2025